The number of genital tract Chlamydia trachomatis infections is steadily increasing worldwide, with approximately 50-70% of infections asymptomatic. There is currently no uniform screening practice, current antibiotic treatment has failed to prevent the increased incidence and there is no vaccine available.
Introduction
Murine studies using C. muridarum have greatly expanded the knowledge of infection kinetics, including the differential cell infiltration between the lower and upper genital tract, the rate at which this occurs, [18] [19] [20] [21] [22] [23] [24] and also the rate of infection ascension. [24] [25] [26] The infectious dose of Chlamydia is known to modulate the innate immune response, with greater inoculating doses causing a greater innate immune response. 26 It has been suggested that due to the greater immune responses elicited by high infectious challenge doses, the infection does not cause as great a degree of hydrosalpinx. 26 However, it has also been shown that while the infectious dose affects the degree of ascension of infection along the female reproductive tract of mice, it does not affect the pathological outcomes, such as hydrosalpinx development and cellular infiltrate. 24 This suggests that, if a similar situation occurs in humans, the development of pathological sequelae may not be affected by the sexual transmission dose. Although the number of Chlamydia required to establish an infection in different strains of mice, 27 and the number of C. caviae transmitted by an infected male guinea pig during mating is known 28 there is no data on these parameters in human infections.
Immunity
The regulation of immune responses against genital tract C. trachomatis infections in humans is largely unknown, due to the difficulty in obtaining samples and monitoring patients long term. Natural immunity to a single infection is known to be short lived, and serovar specific, 29 however multiple infections with different serovars induces longer term, cross serovar immunity. 30 Immune responses to infections are linked to genetic variations, with specific polymorphisms in immune response genes influencing the magnitude of immune responses to microorganisms. 31 There have been reports indicating that women have spontaneously cleared a genital infection without medical intervention, however the exact duration of an infection cannot be determined. 32 It is also believed that antibiotic intervention increases the longer term rates of re-infection due to the inability of the person to develop protective immunity against
Chlamydia. 33 It is widely accepted, based on animal studies, that to resolve a chlamydial genital tract infection in females, both a Th1 and Th2 response needs to be mounted. The infiltration and activation of CD4 + T cells is required for the development of protective immunity and clearance of a primary infection. 34 While clearance of a primary infection is dependent on the development of cell mediated immunity, clearance of a secondary infection requires the presence and production of antibodies. 12, 35 Also an increase in infiltration of 39 and neutrophils. 38 These cells then produce more cytokines such as IFN-γ and TNF-α, which impede further chlamydial growth. Production of various cytokines has, however, proven to be detrimental to the mucosal barrier, with their presence linked to various tissue pathologies, 12 and this has been termed the cellular paradigm 45 ( Fig. 1 ).
Tissue destruction leading to the development of tubal infertility and ectopic pregnancy is caused by the production of cytokines (Fig. 1) , including IL-1 and IL-8, in response to infection. 42 Fallopian tube biopsy samples infected with C. trachomatis, with or without IL-1 receptor antagonist present, revealed that the production of IL-1 leads to destruction of the ciliated epithelium. 42 Toll-like receptor 2 (TLR-2) has also been implicated in the development of chronic pathology development in the mouse model of genital infection, 46 with TLR-2 KO mice producing lower levels of TNF-α and MIP-2, and developing significantly less oviduct pathology. 46 This supports the idea that it is the host's immune response to infection that is responsible for the damage rather than the infection itself.
It has also been suggested that the pathologies seen after an infection are linked to antigenspecific adaptive cellular responses, this is termed the immunological paradigm 47 ( Fig. 1 ).
The exact mechanism or antigen behind the immunological paradigm has yet to be determined. There are conflicting reports that pathogenesis may be linked to chlamydial heat shock protein-60 (cHSP-60) through delayed type hypersensitivity (DTH) or autoimmunity.
Chlamydia can enter a dormant, persistent state, where, in the absence of a productive infection, there is still a low level of immune stimulation from antigen recognition. This low level stimulation is believed to cause chronic inflammatory cell infiltration. 48, 49 Originally, guinea pigs sensitized with Triton-X-100 soluble chlamydial EBs, had greater ocular delayed hypersensitivity when re-exposed to infection at other sites, including vaginal and intestinal infections. 50 Similarly, monkeys immunized against C. trachomatis developed a greater follicular response in the eye upon re-exposure than non-immune controls, 51 highlighting the significance of repeated infections in terms of a delayed hypersensitivity response. T cells isolated from endometrial and salpingeal tissues, removed from PID and tubal factor infertility (TFI) patients, responded to stimulation with cHSP-60 to a greater degree than with chlamydial EBs, further supporting cHSP-60's role in DTH 52, 53 (Fig. 1) . The presence of cHSP-60 antibodies has also been correlated with PID severity, 54-56 TFI 57 and more severe salpingeal pathology. 58 It has also been debated as to whether or not autoimmunity plays a role in the pathogenesis of chlamydial infections ( Fig. 1) , due to the high sequence homology between self and chlamydial HSP-60. 48 A study where mice were immunized with either cHSP-60, mouse trachomatis serovar D contain 4 potential T cell epitopes that display 100% identity. 59, 60 There is still some doubt over how involved cHSP-60 is in the development of autoimmunity, as, in these same experiments, immunization of mice with cHSP-60 alone did not induce cross-reactive autoimmune T cells, 59 however during an actual chlamydial infection it is highly likely that both host and chlamydial HSP-60 are produced.
This highlights that it is not necessarily the damage caused by the infection itself that leads to the development of reproductive sequelae such as PID, but rather the host's immune response to infection that may actually cause the damage.
Treatment or Prevention?
The current recommended treatments for genital tract infections caused by C. trachomatis are azithromycin or doxycycline. 61 Azithromycin is considered more effective due to it being a single 1g dose compared to a 7 days course of doxycycline, thereby enhancing compliance. 61 There is emerging evidence that C. trachomatis is developing antibiotic resistance, with clinical isolates having single and multidrug resistance when cultured in vitro. [62] [63] [64] [65] Isolates have been individually resistant to tetracyclines, macrolides, fluoroquinolones, 64 or resistant to doxycycline, azithromycin and ofloxacin. 65 In addition, a study of infected women, who completed antibiotic treatment, found that 10% of the cohort was re-infected within 1 month of treatment completion, and 13% by 3 months, even though abstinence or 100% condom use was reported. 66 While the shortened duration of infections from early antibiotic treatment has reduced infection-associated reproductive sequelae, the number of case rates continues to increase. 67 This has been suggested to occur because early intervention with antibiotics interferes with the development of protective immune responses, 33 thereby increasing the risk of re-infection, and this has been termed the arrested immunity hypothesis. 67 In light of the increasing rates of C. trachomatis genital infections, the asymptomatic nature of infections and the possibility of antibiotic resistance developing, there is an urgent need for the development of a vaccine that protects both from infection and from the development of pathology. Mathematical modelling has suggested that even a partially protective vaccine will dramatically decrease the rate of spread of infections and reduce economic burden. 68, 69 An efficacious vaccine will need to induce both a strong Th1 cell mediated response and a humoral response. 70 Chlamydia vaccine research has been ongoing for over 20 years, exploring the efficacy of sub-unit, cellular and DNA vaccines, 70, 71 with many advances occurring, but as yet, no fully protective vaccine exists.
The greatest amount of Chlamydia vaccine research to date has focused on sub-unit vaccines.
The use of MOMP as a vaccine candidate has been extensively studied, with varying success. [72] [73] [74] [75] [76] [77] [78] [79] The use of this antigen has resulted from the fact that it constitutes approximately 60% of the outer membrane protein mass of the chlamydial EB. 47 However MOMP contains 4 variable domains, that are surface exposed and are antigenically variable between serovars. 80 This means any vaccine utilizing MOMP as the main antigen will elicit only serovar specific immunity, which is not appropriate considering there are 9 genital serovars (D-L) alone. This highlights that a vaccine containing only MOMP is unlikely to be successful however MOMP could be used as part of a multi-subunit vaccine. However, our recent studies of the serovar distribution of C. trachomatis infections in regional New South
Wales suggest that a MOMP-based vaccine, containing MOMP from serovars E, F and G could potentially protect against >80% of infections in this region. 81 The vaccine candidate at the forefront of current chlamydial vaccine research is chlamydial protease-like activity factor (CPAF), and is possibly the candidate closest to human clinical trials. CPAF has been extensively studied in the murine model of genital infection, [82] [83] [84] [85] [86] [87] and has proven, with the use of adjuvants such as IL-12 and CpG-ODN, 82, 85 to be able to reduce the level of Chlamydia shed from the genital tract and prevent the development of pathology, thereby preserving reproductive health. 82, [84] [85] [86] 88 Due to CPAF being highly conserved between chlamydial species 89 and the fact that transgenic mice expressing human leukocyte antigen (HLA)-DR4 molecules, rather than mouse major histocompatibility complex class II molecules, are able to mount robust protective immune responses,a good candidate for an efficacious vaccine, especially when used in combination with other protective antigens.
Any chlamydial vaccine candidate needs to be able to not only protect the individual from infection but also prevent the development of pathological sequelae such as infertility. This requires a vaccine to induce CD4 + T cell mediated immunity, along with neutralising antibodies and importantly long lasting immunity. As yet, no single candidate is able to do this effectively and will likely require the development of a multi-subunit vaccine.
Problems with vaccine development
The advancement of molecular techniques and availability of immunologically defined animals has allowed the development of vaccine candidates and identified the likely mechanisms of protection. However, there are still many unresolved issues, including how efficacious does a vaccine have to be to prevent further spread and pathology development?
As mentioned previously, mathematical modelling has indicated that even a partially protective vaccine will significantly reduce the health care burden, 68, 69 however, in light of the ability of cytokines secreted from non-immune cells to cause significant reproductive tract tissue destruction, even a low level infection has the ability to cause damage. 90 This suggests that a vaccine designed to prevent pathology development rather than infection may be more cost effective.
There are very few studies that have examined the effects of the timing of vaccination. For example it is unknown if any candidate vaccines have a therapeutic effect, or if immunization after a previously resolved infection will provide additional protection against re-exposure.
Very early studies in humans indicated that individuals that had had previous ocular infections, that were then immunized with a killed whole cell vaccine developed enhanced pathology of the eye upon re-exposure, compared to those that were not immunized. 91 This occurrence was thought to be linked to the high homology seen between cHSP-60 and self-HSP-60, contributing to autoimmunity and pathology development. Due to this, investigations using whole cell vaccines were not continued. This highlights the need to select vaccine antigens that elicit protective immunity but do not enhance pathology, However, women who were we seronegative for HSV-1 and 2 mounted strong anti-HSV-2 immune responses. 106 With genital tract Chlamydia infection rates on the continual rise and the asymptomatic nature of infections, these are important aspects that have yet to be examined in any way.
A vaccine designed to target the mucosal surfaces of the female reproductive tract could also be affected by reproductive cycle-associated changes in female sex hormones. 107 However, any vaccine candidate's efficacy needs to not be affected by the infection status of the individual, and must be able to effectively target the reproductive mucosa, irrespective of the hormonal status.
